ILD

ILD
Name	ILD

ILD ILD is a heterogeneous group of diffuse parenchymal pulmonary disorders characterized by varying degrees of inflammation and fibrosis of the pulmonary interstitium. It presents across diverse patient populations and overlaps with numerous systemic conditions, exposures, and genetic syndromes. Clinical management requires integration of radiologic, pathologic, and multidisciplinary expertise from centers experienced with complex respiratory diseases.

Introduction

The term encompasses entities ranging from idiopathic fibrosing disorders to well-characterized occupational, drug-induced, and connective tissue–associated syndromes. Important historical descriptions and cohort studies emerged from institutions such as Mayo Clinic, Johns Hopkins Hospital, Royal Brompton Hospital, and research networks like the American Thoracic Society and European Respiratory Society. Major contributions to classification and management have been informed by consensus statements issued by the American Thoracic Society and European Respiratory Society.

Classification and Causes

Classification frameworks separate idiopathic conditions, occupational and environmental exposures, drug-induced forms, and disease associated with systemic disorders. Idiopathic entities include groups defined by consensus such as idiopathic pulmonary fibrosis (IPF) described in guidelines from the American Thoracic Society and European Respiratory Society. Occupational and environmental causes implicate agents documented in industrial and public health literature from Occupational Safety and Health Administration investigations, miners studied in cohorts from University of Utah and University of Kentucky, and historical outbreaks like those reported near Wittenoom mines. Drug-induced cases have been linked to agents developed or regulated by organizations including GlaxoSmithKline, Pfizer, and chemotherapeutics used in protocols at centres such as Memorial Sloan Kettering Cancer Center. Connective tissue associations include manifestations in patients with diagnoses made at specialty centers like Mayo Clinic for disorders such as systemic sclerosis managed at Johns Hopkins Hospital and Massachusetts General Hospital clinics.

Pathophysiology

Pathogenic mechanisms reflect aberrant wound healing, extracellular matrix remodeling, and persistent fibroblast activation described in mechanistic studies from laboratories at Harvard Medical School, Stanford University School of Medicine, and the National Institutes of Health. Molecular pathways implicated derive from experiments referencing profibrotic mediators studied in the context of signaling axes explored at institutions such as University of California, San Francisco and Karolinska Institute. Genetic predisposition has been mapped in cohorts coordinated by groups including Genentech collaborations and academic centers like University of Chicago uncovering variants in telomere-related genes and surfactant-associated genes characterized in studies from Brigham and Women's Hospital and Mount Sinai Health System.

Clinical Presentation and Diagnosis

Patients typically present with progressive exertional dyspnea, nonproductive cough, and auscultatory findings described in clinical practice manuals used at Cleveland Clinic, Mayo Clinic, and training sites like University College London Hospitals. Key diagnostic modalities include high-resolution computed tomography as standardized by radiology departments at Mayo Clinic and Massachusetts General Hospital, pulmonary function testing protocols adopted at Johns Hopkins Hospital, and multidisciplinary discussions modeled after tumor-board–style meetings at centers such as Royal Brompton Hospital and Guy's and St Thomas' NHS Foundation Trust. Histopathologic correlation from thoracoscopic biopsies is performed in pathology services like those at Johns Hopkins Hospital and Boston Medical Center. Differential considerations draw on conditions described in specialty texts from Oxford University Press and consensus documents from American Thoracic Society.

Management and Treatment

Therapeutic strategies combine antifibrotic agents, immunomodulatory therapy, and supportive interventions. Antifibrotic drugs developed by companies like Boehringer Ingelheim and Roche are prescribed per trials conducted with oversight by institutions including National Institutes of Health and cooperative groups such as the Pulmonary Fibrosis Foundation. Immunosuppressive regimens are used in cases linked to connective tissue disorders treated at centers including Brigham and Women's Hospital and Mayo Clinic. Nonpharmacologic care includes pulmonary rehabilitation programs modeled on protocols from Cleveland Clinic and oxygen therapy infrastructure similar to services at Vanderbilt University Medical Center. Advanced options such as lung transplantation are coordinated through transplant centers like UCLA Health, University of Pittsburgh Medical Center, and Toronto General Hospital, with perioperative and long-term care drawing on transplant registries maintained by organizations such as the International Society for Heart and Lung Transplantation.

Prognosis and Complications

Prognosis varies widely from stable disease to progressive fibrosis with respiratory failure; survival estimates and outcome research are reported in longitudinal cohorts from Norwegian University of Science and Technology, University of Toronto, and multicenter registries compiled by the Pulmonary Fibrosis Foundation. Complications include pulmonary hypertension managed by specialists at centers like Cleveland Clinic and increased risk of acute exacerbations documented in case series from Massachusetts General Hospital. Comorbidities such as coronary artery disease and malignancy are addressed in multidisciplinary programs at institutions including Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center. Ongoing clinical trials and translational research led by groups at University of California, San Francisco, Imperial College London, and University of Sydney continue to refine prognostic markers and therapeutic options.

Category:Respiratory diseases